ST. LOUIS--(BUSINESS WIRE)--
At the 63rd ASMS Conference on Mass Spectrometry & Allied
Topics (ASMS), Bruker (NASDAQ: BRKR) announced the launch of the novel MALDI
Tissuetyper solution, based on the new rapifleX MALDI-TOF
Mass Spectrometry system.
This Smart News Release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20150601005091/en/
Bruker's MALDI Tissuetyper Solution (Photo: Business Wire)
The introduction of the revolutionary rapifleX as the new
instrument platform for MALDI imaging anatomical pathology research
further enhances Bruker’s leadership position for MALDI-TOF-based
applications solutions. The new rapifleX system eliminates
many previous bottlenecks in mass spectrometry imaging (MSI), with much
improved speed, throughput, ease-of-use, robustness and spatial
resolution. At the same time, MSI maintenance efforts are reduced to a
minimum by a streamlined design of the ion source for maximum uptime and
optimized accessibility.
The new MALDI Tissuetyper solution based on the rapifleX
instrument redefines the key performance measures for MALDI imaging and
allows for completely new projects and measurement strategies. The rapifleX
system offers by far the highest laser repetition rate on the market,
combined with the best MALDI imaging spatial resolution. The instrument
has a removable, self-aligning ion source for highest customer service
convenience.
The MALDI Tissuetyper solution works up to 20 times faster
than traditional MALDI-TOF systems, using Bruker’s break-through,
proprietary smartbeam™ 3D laser. The new scanning smartbeam
3D laser provides a fast moving laser-beam which is synchronized
with the movement of the MALDI target stage. In combination with the
game-changing laser repetition rate of 10 kHz, this architecture allows
for real high throughput where MALDI imaging researchers have
dramatically increased flexibility in pixel size or target tissue size.
Depending on the sample size, typical tissue sections can now be imaged
in approximately 30 minutes. Mass spectrometry images from small tissue
biopsies are available within a few minutes.
Tissue-typing of protein signature distributions continues to be one of
the most powerful techniques available in areas such as anatomical
pathology or biomarker research. Current research results indicate
potential future clinical pathology applications in tumor staging,
supporting therapy decisions or disease prognosis. The MALDI
Tissuetyper offers exclusive statistical analysis software and
bioinformatics tools for data mining, as well as visualization of
two-dimensional and even three-dimensional imaging datasets from
multiple tissue sections.
Dr. Ron M.A. Heeren, Professor for Molecular Imaging at Maastricht
University, The Netherlands, said: “Translational clinically oriented
research with mass spectrometry imaging (MSI) is critically dependent on
speed and robust operation. Current instrumentation has been limiting
its full adaptation. The new rapifleX-based MALDI
Tissuetyper solution allows us to finally overcome that
limitation. It enables us to engage in high-throughput clinical studies
and establishes MSI as a powerful and reliable information source for
personalized medicine.”
Professor Dr. Axel Walch, Head of the Department for Analytical
Pathology, Institute of Pathology, at the Helmholtz-Center in Munich,
Germany, added: “The analysis of tumor heterogeneity is one of the most
important biomedical research challenges in oncology and personalized
medicine. MALDI imaging is perfectly suited to get an unbiased molecular
view on tumor heterogeneity. The speed and performance of the MALDI
Tissuetyper solution gives us for the first time the possibility
to analyze even large tumor specimen over meaningful patient cohorts
with sufficient spatial resolution to get a comprehensive understanding
of tumor heterogeneity.”
Dr. Wolfgang Pusch, Executive Vice President for Clinical MALDI
Solutions at Bruker Daltonics, commented: “The ease-of-use and
throughput capabilities make the new rapifleX MALDI-TOF
the platform of choice for clinical research applications in anatomical
pathology. Bruker is committed to drive the MALDI Tissuetyper
solution not only for mass spectrometry applications, but more and more
also in anatomical pathology workflows. For this application, the rapifleX
is far ahead concerning speed, throughput, robustness, uptime and
ease-of-use.”
About the Bruker MALDI Tissuetyper
The MALDI Tissuetyper solution enables to use MALDI-TOF
mass spectrometry as a powerful mass spectrometry imaging (MSI) tool,
which is highly complementary to traditional imaging technologies in
histology. The MALDI Tissuetyper extracts molecular
information as a proteomic fingerprint, which displays peptides and
small proteins. In contrast to traditional histological tissue analysis,
the MALDI Tissuetyper does neither require a molecular
probe nor an antibody. The MALDI Tissuetyper offers
multiplex analysis of multiple potential biomarkers simultaneously in an
untargeted approach. The MALDI Tissuetyper provides
complementary information to immunohistochemistry (IHC) and in many
cases can differentiate cell populations that cannot easily be
differentiated by IHC. In additionally, it might save valuable biopsy
material, in cases where only limited tissue sample is available. The MALDI
Tissuetyper can be used for biomarker discovery studies, but
also for multi-marker tissue-typing and classification. The MALDI
Tissuetyper is for research use only.
About Bruker Corporation (NASDAQ: BRKR)
For more than 50 years, Bruker has enabled scientists to make
breakthrough discoveries and develop new applications that improve the
quality of human life. Bruker’s high-performance scientific research
instruments and high-value analytical solutions enable scientists to
explore life and materials at molecular, cellular and microscopic levels.
In close cooperation with our customers, Bruker is enabling innovation,
productivity and customer success in life science molecular research, in
applied and pharma applications, in microscopy, nano-analysis and
industrial applications, as well as in cell biology, preclinical
imaging, clinical research, microbiology and molecular diagnostics. For
more information, please visit: http://www.bruker.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150601005091/en/
Source: Bruker Corporation